Albertsons Companies Earnings Call Transcripts
Fiscal Year 2026
-
Q4 and FY25 results exceeded expectations despite pharmacy headwinds, with strong digital and loyalty growth, disciplined capital allocation, and a raised productivity target. FY26 guidance anticipates modest sales growth, margin resilience, and continued investment in technology and stores.
-
Q3 2025 delivered 2.4% identical sales growth and 21% digital sales growth, with strong pharmacy and digital performance. Guidance for fiscal 2025 was narrowed, reflecting pharmacy headwinds, but productivity and AI initiatives are driving margin improvement and long-term growth.
-
Q1 2025 saw 2.8% identical sales growth, led by digital and pharmacy, but with lower margins due to value investments. Guidance for FY2025 was raised for sales growth, with productivity expected to offset margin pressures in the second half.
Fiscal Year 2025
-
Q4 saw 2.3% ID sales growth, strong digital and pharmacy gains, and $855M adjusted EBITDA. Fiscal 2025 guidance targets 1.5%-2.5% ID sales growth, $3.8-$3.9B adjusted EBITDA, and continued investment in digital, loyalty, and productivity initiatives.
-
Q3 2024 saw 2% identical sales growth, strong digital and pharmacy gains, and a 25% dividend hike. Guidance for Adjusted EBITDA and EPS was raised, with productivity and technology investments driving efficiency. Cautious consumer trends and competitive pressures persist.